Hanjing Emily Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hanjing Emily Wu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Blake Lackey
Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2 shared publications - Dachun Chen
Beijing Huilongguan Hospital, Peking University, Beijing 100871, China
2 shared publications - Dongmei Wang
State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
2 shared publications - Meihong Xiu
Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China
2 shared publications - Pinhong Chen
Beijing Institute of Basic Medical Sciences, Beijing, China
2 shared publications - Xiang Yang Zhang
State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 29 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6414
Association of Transferrin Gene Polymorphism with Cognitive Deficits and Psychiatric Symptoms in Patients with Chronic Schizophrenia
A large amount of recent literature has focused on impaired iron homeostasis in the pathophysiology of schizophrenia. Specifically, microarray analysis has illustrated associations between the transferrin locus and schizophrenia. To elaborate on the effects of transferrin on schizophrenia and its psychiatric phenotypes, our study aimed to investigate whether transferrin gene polymorphism was correlated with cognitive deficits and clinical symptoms in schizophrenia. We recruited 564 patients with chronic schizophrenia and 422 healthy controls (HCs) in a Han Chinese population, collected phenotypic data, and genotyped the rs3811655 polymorphism of the transferrin gene. Our results showed that the rs3811655 polymorphism was related to cognitive performance in both patients and HCs, as well as negative symptoms in patients (all p < 0.05), and patients carrying at least one G-allele showed worsened cognition/severe negative symptoms (all p < 0.05). Further analyses also found that the rs3811655 polymorphism in combination with cognition may exert small but significant contributions to the negative (β = −0.10, t = −2.48, p < 0.05) or total psychiatric symptoms (β = −0.08, t = −1.92, p < 0.05) in patients. Our findings indicated that the rs3811655 polymorphism may be implicated in the cognitive deficits of schizophrenia and HCs as well as psychiatric symptoms in patients, which suggested the possible iron regulatory mechanism in the pathology of schizophrenia.
- 29 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6414
Open AccessAssociation of Transferrin Gene Polymorphism with Cognitive Deficits and Psychiatric Symptoms in Patients with Chronic Schizophrenia
A large amount of recent literature has focused on impaired iron homeostasis in the pathophysiology of schizophrenia. Specifically, microarray analysis has illustrated associations between the transferrin locus and schizophrenia. To elaborate on the effects of transferrin on schizophrenia and its psychiatric phenotypes, our study aimed to investigate whether transferrin gene polymorphism was correlated with cognitive deficits and clinical symptoms in schizophrenia. We recruited 564 patients with chronic schizophrenia and 422 healthy controls (HCs) in a Han Chinese population, collected phenotypic data, and genotyped the rs3811655 polymorphism of the transferrin gene. Our results showed that the rs3811655 polymorphism was related to cognitive performance in both patients and HCs, as well as negative symptoms in patients (all p < 0.05), and patients carrying at least one G-allele showed worsened cognition/severe negative symptoms (all p < 0.05). Further analyses also found that the rs3811655 polymorphism in combination with cognition may exert small but significant contributions to the negative (β = −0.10, t = −2.48, p < 0.05) or total psychiatric symptoms (β = −0.08, t = −1.92, p < 0.05) in patients. Our findings indicated that the rs3811655 polymorphism may be implicated in the cognitive deficits of schizophrenia and HCs as well as psychiatric symptoms in patients, which suggested the possible iron regulatory mechanism in the pathology of schizophrenia.
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 28 (4) , 310-318
A Retrospective Study of the Adjunctive Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal
Benzodiazepine withdrawal is a widespread problem with potentially severe and deadly consequences. Currently, the only medications available for treating benzodiazepine withdrawal are short-acting and long-acting benzodiazepines. Identifying other drugs to help in treating benzodiazepine withdrawal is necessary. Gabapentin, an anxiolytic drug that is also used off-label to treat alcohol withdrawal, is a potential candidate for modulating benzodiazepine withdrawal. Using electronic records from a large inpatient psychiatric facility, a retrospective study of 172 patients presenting with benzodiazepine withdrawal was conducted to determine if the coincidental use of gabapentin for other medical conditions was associated with better outcomes of benzodiazepine withdrawal (N=57 gabapentin, N=115 no gabapentin). The primary outcomes were hospital length of stay and total amount of benzodiazepines given (lorazepam milligram equivalent). In this retrospective analysis of electronic medical record data, the patients experiencing benzodiazepine withdrawal who received gabapentin as an adjunct to the use of benzodiazepines were administered a smaller amount of benzodiazepines and had a shorter length of hospital stay relative to the comparison group who did not receive adjunctive gabapentin. These results suggest the potential use of gabapentin as an adjunct to the use of benzodiazepines for treating benzodiazepine withdrawal. The limitations of this study included a small sample size and variability in medication management strategies across the sample.
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 28 (4) , 310-318
A Retrospective Study of the Adjunctive Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal
Benzodiazepine withdrawal is a widespread problem with potentially severe and deadly consequences. Currently, the only medications available for treating benzodiazepine withdrawal are short-acting and long-acting benzodiazepines. Identifying other drugs to help in treating benzodiazepine withdrawal is necessary. Gabapentin, an anxiolytic drug that is also used off-label to treat alcohol withdrawal, is a potential candidate for modulating benzodiazepine withdrawal. Using electronic records from a large inpatient psychiatric facility, a retrospective study of 172 patients presenting with benzodiazepine withdrawal was conducted to determine if the coincidental use of gabapentin for other medical conditions was associated with better outcomes of benzodiazepine withdrawal (N=57 gabapentin, N=115 no gabapentin). The primary outcomes were hospital length of stay and total amount of benzodiazepines given (lorazepam milligram equivalent). In this retrospective analysis of electronic medical record data, the patients experiencing benzodiazepine withdrawal who received gabapentin as an adjunct to the use of benzodiazepines were administered a smaller amount of benzodiazepines and had a shorter length of hospital stay relative to the comparison group who did not receive adjunctive gabapentin. These results suggest the potential use of gabapentin as an adjunct to the use of benzodiazepines for treating benzodiazepine withdrawal. The limitations of this study included a small sample size and variability in medication management strategies across the sample.
- Open Access
- 6 January 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 125
Polymorphism of Transferrin Gene Impacts the Mediating Effects of Psychotic Symptoms on the Relationship between Oxidative Stress and Cognition in Patients with Chronic Schizophrenia
A series of studies indicated that iron distribution that partly derives from transferrin-bound iron in the peripheral nervous system in the brain may act in processes such as myelination and brain development. However, the relationship between schizophrenia, its psychotic symptoms, and the transferrin (TF) gene has not been systematically explored. Our study aimed to investigate how a particular polymorphism of the transferrin gene, rs3811655, affects the superoxide dismutase (SOD), malondialdehyde (MDA), psychotic symptoms, cognition, or the mediation model between antioxidant enzymes and cognition via symptoms. A total of 564 patients with chronic schizophrenia and 468 healthy control subjects were recruited. The psychotic symptoms and cognition were assessed by the Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), respectively. Furthermore, the serum SOD, MDA activity, and transferrin gene polymorphism were measured in patients. Our results demonstrated that patients with the G allele possessed more severe negative symptoms, worse cognitive performance with respect to attention, and higher serum Mn-SOD activity. Additionally, the rs3811655 polymorphism may act as a moderator in the association between Cu/Zn-SOD activity and cognition, as well as psychotic symptoms in patients suffering from schizophrenia. According to this study, the single nucleotide polymorphism (SNP) rs3811655 polymorphism may fail to contribute to the susceptibility of schizophrenia in an individual but is involved in the iron-induced oxidative stress disturbance and cognitive impairment in schizophrenia. This deepens our understanding of the critical role of iron-induced oxidative stress that might underlie the pathophysiology of schizophrenia.
- 6 January 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 125
Open AccessPolymorphism of Transferrin Gene Impacts the Mediating Effects of Psychotic Symptoms on the Relationship between Oxidative Stress and Cognition in Patients with Chronic Schizophrenia
A series of studies indicated that iron distribution that partly derives from transferrin-bound iron in the peripheral nervous system in the brain may act in processes such as myelination and brain development. However, the relationship between schizophrenia, its psychotic symptoms, and the transferrin (TF) gene has not been systematically explored. Our study aimed to investigate how a particular polymorphism of the transferrin gene, rs3811655, affects the superoxide dismutase (SOD), malondialdehyde (MDA), psychotic symptoms, cognition, or the mediation model between antioxidant enzymes and cognition via symptoms. A total of 564 patients with chronic schizophrenia and 468 healthy control subjects were recruited. The psychotic symptoms and cognition were assessed by the Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), respectively. Furthermore, the serum SOD, MDA activity, and transferrin gene polymorphism were measured in patients. Our results demonstrated that patients with the G allele possessed more severe negative symptoms, worse cognitive performance with respect to attention, and higher serum Mn-SOD activity. Additionally, the rs3811655 polymorphism may act as a moderator in the association between Cu/Zn-SOD activity and cognition, as well as psychotic symptoms in patients suffering from schizophrenia. According to this study, the single nucleotide polymorphism (SNP) rs3811655 polymorphism may fail to contribute to the susceptibility of schizophrenia in an individual but is involved in the iron-induced oxidative stress disturbance and cognitive impairment in schizophrenia. This deepens our understanding of the critical role of iron-induced oxidative stress that might underlie the pathophysiology of schizophrenia.
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Reviews
- Vol. 14 (2) , 99-104
MR Spectroscopy Findings of the Basal Ganglia in Bipolar Disorders: A Systematic Review
Objective: Magnetic Resonance Spectroscopy (MRS) is a noninvasive in vivo technique extensively applied to assess the levels of neural metabolites in the brain. We aimed to summarize the findings of proton spectroscopy (H-1 MRS) studies addressing neuro-metabolite findings in the Basal Ganglia (BG) of patients with Bipolar Disorders (BD). Method: A search of PubMed and Ovid databases was conducted to identify H-1 MRS studies since 1990 reporting N-acetylaspartate (NAA), phosphocholine plus glycerophosphocholine (PC+GPC), and creatine plus phosphocreatine (Cr+PCr) levels in the BG of patients with BD. Results: Ten original studies were included in this review. Three studies involved BD patients with depressed mood, six studied euthymic BD patients, and one study looked at manic subjects. In depressed BD patients, three studies reported elevated PC+GPC and Cr+PCr levels in the caudate and putamen. NAA levels were found to be elevated in two of the studies, while one reported no change. In euthymic BD patients, five studies reported no group differences with respect to any metabolites, and one study found differences in PC+GPC/Cr+PCr associated with lithium treatment. In mania, lower PC+GPC, lower NAA levels, and increased Cr+PCr levels were described in the caudate of BD patients compared to HC. Conclusion: This review suggests that abnormalities in NAA, GPC+PC, and Cr+PCr levels in the BG might be associated with mood state among BD patients. In addition, the methodological issues involved in the heterogeneity of H-1 MRS findings in BD, as well as the potential role of H-1 MRS findings as biomarkers for BD, are discussed.
- 1 January 2018
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Reviews
- Vol. 14 (2) , 99-104
MR Spectroscopy Findings of the Basal Ganglia in Bipolar Disorders: A Systematic Review
Objective: Magnetic Resonance Spectroscopy (MRS) is a noninvasive in vivo technique extensively applied to assess the levels of neural metabolites in the brain. We aimed to summarize the findings of proton spectroscopy (H-1 MRS) studies addressing neuro-metabolite findings in the Basal Ganglia (BG) of patients with Bipolar Disorders (BD). Method: A search of PubMed and Ovid databases was conducted to identify H-1 MRS studies since 1990 reporting N-acetylaspartate (NAA), phosphocholine plus glycerophosphocholine (PC+GPC), and creatine plus phosphocreatine (Cr+PCr) levels in the BG of patients with BD. Results: Ten original studies were included in this review. Three studies involved BD patients with depressed mood, six studied euthymic BD patients, and one study looked at manic subjects. In depressed BD patients, three studies reported elevated PC+GPC and Cr+PCr levels in the caudate and putamen. NAA levels were found to be elevated in two of the studies, while one reported no change. In euthymic BD patients, five studies reported no group differences with respect to any metabolites, and one study found differences in PC+GPC/Cr+PCr associated with lithium treatment. In mania, lower PC+GPC, lower NAA levels, and increased Cr+PCr levels were described in the caudate of BD patients compared to HC. Conclusion: This review suggests that abnormalities in NAA, GPC+PC, and Cr+PCr levels in the BG might be associated with mood state among BD patients. In addition, the methodological issues involved in the heterogeneity of H-1 MRS findings in BD, as well as the potential role of H-1 MRS findings as biomarkers for BD, are discussed.